Loading
Bile duct cancers are named by where they start: inside the liver, at the hilum where the ducts join, in the lower duct near the pancreas, or in the gallbladder. Each behaves and mutates differently.
Intrahepatic cholangiocarcinoma (iCCA) carries FGFR2 fusions (~10-15%) and IDH1 mutations (~15%) and is rising in incidence; perihilar (Klatskin) and distal tumours are more often HER2-amplified or KRAS-mutant; gallbladder cancer has the highest HER2 prevalence (~15-20%) and is common in Chile, India and among Indigenous Americans. Molecular profiling is guideline-recommended for all advanced biliary cancers.
In plain words · FGFR2 is a growth receptor fused in bile-duct cancer and overproduced in gastric cancer.
Showing the target this term concerns: FGFR2.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.